ResMed (RMD) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($11.88 million) and the uptick to downtick ratio was 0.49. The transaction value on upticks was $11.49 million and on downticks, the transaction value was $23.37 million. In block trades, the transaction value of inflow done during uptick was $0.86 million. The transaction value of block trades during downticks was $12.3 million. The uptick to downtick block trade ratio was 0.07. The money flow was negative ($11.43 million), indicating the traders were booking profit on the price strength. ResMed (RMD) rose $0.43 at $67.12, during intraday Friday , a rise of 0.64% over the previous days close.
The company Insiders own 2.54% of ResMed shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -36.15% . Institutional Investors own 61.29% of ResMed shares. During last six month period, the net percent change held by insiders has seen a change of -36.15%.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Resmed Inc, Pace Gary W had sold 36,000 shares worth of $2,517,480 in a transaction dated August 19, 2016. In this transaction, 36,000 shares were sold at $69.93 per share.
ResMed (NYSE:RMD): stock was range-bound between the intraday low of $66.855 and the intraday high of $67.47 after having opened at $66.89 on Fridays session. The stock finally closed in the red at $66.89, a loss of -0.09%. The stock remained in the red for the whole trading day. The total traded volume was 740,305 shares. The stock failed to cross $67.47 in Fridays trading. The stocks closing price on Thursday was $67.12.
ResMed (RMD) : During the past 4 weeks, traders have been relatively bearish on ResMed (RMD), hence the stock is down -3.87% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.34% relative to the S&P 500. The 4-week change in the price of the stock is -3.99% and the stock has fallen -2.85% in the past 1 week.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.